Trials / Completed
CompletedNCT00099970
Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy
Phase II Open-Label Study of Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemo
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (planned)
- Sponsor
- PDL BioPharma, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial is being conducted to determine tumor response and preliminary safety of a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin) that is required for the establishment of new blood vessels during tumor growth, a process known as angiogenesis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | M200 (volociximab) in Combination with Dacarbazine (DTIC) |
Timeline
- Start date
- 2004-12-01
- Completion
- 2006-03-01
- First posted
- 2004-12-22
- Last updated
- 2008-08-05
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00099970. Inclusion in this directory is not an endorsement.